Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Infliximab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 8Flixabi

    02 2Inflectra

    03 6Inflectra/Remsima

    04 26Remicade

    05 2Remicade

    06 3Renflexis

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Remicade

    Infliximab

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Remicade

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Johnson & Johnson

    Infliximab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 3,747

    2019 Revenue in Millions : 4,380

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Flixabi

    Infliximab?

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Flixabi

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Infliximab?

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 98

    2019 Revenue in Millions : 68

    Growth (%) : 44

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Inflectra/Remsima

    Infliximab

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Inflectra/Remsima

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Pfizer Inc.

    Infliximab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 625

    2018 Revenue in Millions : 642

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Remicade

    Infliximab

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Remicade

    Japan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Mitsubishi Tanabe

    Infliximab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 427

    2019 Revenue in Millions : 509

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Flixabi

    Infliximab?

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Flixabi

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biogen

    Infliximab?

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 99

    2020 Revenue in Millions : 98

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Inflectra/Remsima

    Infliximab

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Inflectra/Remsima

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Pfizer Inc.

    Infliximab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 659

    2019 Revenue in Millions : 625

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Remicade

    Infliximab

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Remicade

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Merck

    Infliximab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 330

    2019 Revenue in Millions : 411

    Growth (%) : -20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Remicade

    Infliximab

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Remicade

    Japan
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Mitsubishi Tanabe

    Infliximab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 348

    2020 Revenue in Millions : 422

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Renflexis

    Infliximab-abda

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Renflexis

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Organon

    Infliximab-abda

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 186

    2020 Revenue in Millions : 135

    Growth (%) : 38

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Remicade

    Infliximab

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Remicade

    U.S.A
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Johnson & Johnson

    Infliximab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 3,190

    2020 Revenue in Millions : 3,747

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF